glp-1 receptor agonists effects on cardiovascular risk reduction and mortality outcomes with vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study | Diabetologia Cardiovascular Effects and Tolerability of
Description
These medications, which mimic hormones that regulate appetite, vary in their formulation, dosing schedules, and approved uses
In addition, these agents alleviate hyperandrogenism through inhibition of AMPK-activation-mediated expression of CYP17A1 (173)
doi:10.1515/jpem-2013-0122 90
StenlidRCereniusSYManellHKkemre AydinBMrwaldKGomahrJet al
The numbers tell the story: patients on these medications have higher rates of retained gastric contents during esophagogastroduodenoscopy (EGD) compared to non-users 8.07% versus 3.49% [14]
doi: 10.1136/bmj.g7607 [DOI] [PubMed] [Google Scholar] 2
